1）Chapman KR, et al. Regular vs as needed
inhaled salbutamol in asthma control. Lancet 1994; 343:1379-82.
2）Taylor DR, et al. Regular inhaled beta agonist in asthma:
effects on exacerbations and lung function. Thorax 1993; 48:134-8.
3）Suissa S, et al. Effectiveness of the leukotriene receptor
antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind,
placebo-controlled trial. Ann Intern Med 1997; 126:177-83.
4）Barnes NC, et al. Pranlukast, a novel leukotriene receptor
antagonist: results of the first European, placebo controlled, multicenter
clinical study in asthma. Thorax 1997; 52:523-7.
5）Busse W, et al. Low-dose fluticasone propionate compared
with montelukast for first-line treatment. J Allergy Clin Immunol 2001;
107:461-8.
6）Dempsey OJ, et al. Intravenous mentelukast in acute
asthma: expensive aminophyllie? Thorax 2000; 55:808-9.
7）Biermer L, et al. Montelukast or salmeterol combined
with an inhaled steroid in adult asthma: design and rationale of a randomized,
double-blind comparative study. Respir Med 2000; 94:612-21.
8）Korenblat PE, et al. The role of antileukotrienes in
the treatment of asthma. Ann Allergy Asthma Immunol 2001; 86:31-9.
9）Spina D. The potential of PDE4 inhibitors in asthma
or COPD. Curr Opin Investig Drugs 2000; 1:204-13.
10）Bundschuh DS, et al. In vivo efficacy in airway disease
models of roflumilast, novel orally active PDE4 inhibitor. J Pharmacol
Exp Ther 2001; 297:280-90.
11）Charpiot B, et al. Disease activated drugs: a new
concept for the treatment of asthma. Bioorg Med Chem 2001; 9:1793-805.
12）Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block
LH. A preliminary study of long-term treatment with interferon gamma-1b
and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.
N Engl J Med 1999; 21:1264-9.
13）Gurujeyalakshmi G, et al. Pirfenidone inhibits PDGF
isoforms in bleomycin hamster model of lung fibrosis at the translational
level. Am J Physiol. 1999 ; 276:L311-8.
14）Raghu G, et al. Treatment of idiopathic pulmonary
fibrosis with a new antifibrotic agent, Pirfenidone: results of a propective,
open-label Phase II study. Am J Respir Crit Care Med 1999; 159:1061-9.
15）Nicod LP. Pirfenidone in idiopathic pulmonary fibrosis.
Lancet 1999; 24:268-9.
16）Cox G, et al: A biological staging model for operable
non-small cell lung cancer. Thorax 2001; 56:561-6.
17）Nakagawa K. Tyrosin kinase inhibitors-solid cancers.
Gan To Kagaku Ryoho 2001; 28:608-13.
18)Sirotnak FM, et al. Efficacy of cytotoxic agents
against human tumor xenograft markedly enhanced by coadministration
of ZD1839 (Iressa), inhibitor of EGFR tyrosine kinase. Clin Cancer Res
2000; 6:4885-92.